Saturday 17 October 2026
Export REVB’s income statement to Excel — free account
Revelation Biosciences, Inc.
REVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.9% and free cash flow fell 35.3%, each against the same quarter a year earlier.
0.49
0.27
−35.53%
Follow REVB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
6.92 | 5.41 | 10.02 | 6.21 |
Net Debt/EBITDA |
6.56 | 4.17 | 4.57 | 3.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.34 | 0.78 | 0.37 | 0.77 | |
Capex/Depreciation |
0.00 | 0.00 | (9.99) | (4.77) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(2.40) | (3.17) | (1.02) | (0.68) | |
Cash per Share |
19.22 | 17.23 | 4.40 | 3.00 | |
Shareholders Equity per Share |
16.64 | 14.27 | 4.05 | 2.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.64 | 14.27 | 4.05 | 2.63 | |
Free Cash Flow |
(1.59) | (1.97) | (3.29) | (2.60) | |
Working Capital |
10.98 | 8.81 | 12.79 | 9.80 | |
Capital Expenditures |
— | — | (0.07) | (0.04) | |
Net Current Asset Value |
10.98 | 8.09 | 12.15 | 9.25 | |
| Other line items | |||||
Quick Ratio |
6.85 | 5.36 | 9.96 | 6.11 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.40) | (3.17) | (1.00) | (0.67) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.01) | |
Average Payables |
2.08 | 0.68 | 0.73 | 0.88 | |
Average Assets |
9.80 | 9.10 | 9.51 | 8.95 | |
Average Common Equity |
6.84 | 6.78 | 7.93 | 6.95 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates